Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Update

Spero Therapeutics, Inc. (NASDAQ:SPRO) was the target of a large drop in short interest in the month of February. As of February 27th, there was short interest totaling 574,027 shares, a drop of 19.8% from the February 12th total of 715,694 shares. Based on an average trading volume of 270,567 shares, the short-interest ratio is presently 2.1 days. Approximately 1.1% of the company’s shares are short sold. Approximately 1.1% of the company’s shares are short sold. Based on an average trading volume of 270,567 shares, the short-interest ratio is presently 2.1 days.

Insider Buying and Selling at Spero Therapeutics

In related news, insider Esther Rajavelu sold 87,917 shares of Spero Therapeutics stock in a transaction on Friday, February 6th. The shares were sold at an average price of $2.36, for a total transaction of $207,484.12. Following the transaction, the insider owned 1,012,091 shares in the company, valued at approximately $2,388,534.76. The trade was a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Spero Therapeutics

Hedge funds have recently bought and sold shares of the business. GSK plc acquired a new position in shares of Spero Therapeutics in the 4th quarter valued at approximately $21,414,000. Stonepine Capital Management LLC bought a new stake in shares of Spero Therapeutics in the second quarter worth $455,000. Arrowstreet Capital Limited Partnership acquired a new stake in Spero Therapeutics in the third quarter valued at $283,000. OMERS ADMINISTRATION Corp bought a new position in Spero Therapeutics during the 4th quarter valued at $306,000. Finally, Squarepoint Ops LLC acquired a new position in Spero Therapeutics during the 4th quarter worth $278,000. Institutional investors and hedge funds own 25.60% of the company’s stock.

Spero Therapeutics Stock Down 0.4%

Shares of Spero Therapeutics stock traded down $0.01 during trading hours on Friday, hitting $2.58. 200,259 shares of the company’s stock traded hands, compared to its average volume of 300,505. Spero Therapeutics has a twelve month low of $0.51 and a twelve month high of $3.22. The company has a market cap of $145.36 million, a PE ratio of -3.27 and a beta of 1.45. The stock has a 50 day simple moving average of $2.37 and a 200-day simple moving average of $2.28.

Analysts Set New Price Targets

SPRO has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen raised Spero Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, January 11th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce”.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.